Crespo, Javier http://orcid.org/0000-0001-8248-0172
Cabezas, Joaquín http://orcid.org/0000-0003-0012-484X
Calleja, José Luis
Buti, María
Lazarus, Jeffrey V. http://orcid.org/0000-0001-9618-2299
Article History
First Online: 27 July 2023
Competing interests
: J. Crespo has been a consultant and/or speaker and/or participated in sponsored clinical trials and/or received grants and research support from Gilead Sciences, AbbVie, MSD, Shionogi, Intercept Pharmaceuticals, Janssen Pharmaceuticals Inc., Celgene and Alexion, outside of the submitted work. He is also a member of the Scientific Committee of the Strategic Plan for the Management of Hepatitis C of the Spanish National Health System. J. Cabezas declares lecture fees from, grants from and advisory board participation for Gilead and AbbVie, outside of the submitted work. J.L.C. declares consultant and lectures fees from Gilead Sciences, AbbVie, MSD and Roche, outside of the submitted work. M.B. declares speaker fees from and advisory board participation for Gilead, AbbVie and Janssen and a grant from Gilead, outside of the submitted work. J.V.L. acknowledges grants and speaker fees from AbbVie, Gilead Sciences, MSD and Roche Diagnostics to his institution, speaker fees from Intercept, Janssen, Novo Nordisk and ViiV and consulting fees from Novavax, outside of the submitted work. He also acknowledges support to ISGlobal from the grant CEX2018-000806-S funded by MCIN/AEI/10.13039/501100011033 and the ‘Generalitat de Catalunya’ through the CERCA Program, outside of the submitted work.